All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

pittsburgh

atlanta

san-diego

charlotte

boulder

washington-dc

kansas-city

dallas

denver

detroit

des-moines

austin

boston

chicago

cleveland

columbus

houston

indianapolis

miami

nashville

new-orleans

nw-arkansas

philadelphia

phoenix

portland

richmond

salt-lake-city

san-antonio

san-francisco

seattle

tampa-bay

twin-cities

raleigh

huntsville

colorado-springs

axios-local

axios-pro

axios-live

the-axios-show

Lee Equity is exploring the sale of Inception Fertility, the largest IVF care provider in the U.S., multiple sources tell Axios.

Driving the news: A sale process formally kicked off in June, with first-round bids submitted last week, sources say. 

Moelis is providing sell-side advice, they say, with the process expected to garner interest from both standalone sponsors and strategics. 

By the numbers: Inception, based in Bellaire, Texas, is forecasting approximately $90 million of 2022 pro forma adjusted EBITDA, including pending M&A, the sources say. 

It's too early to peg valuation, they say, but high-growth health care services assets have tended to fetch mid- to high-teens multiples, with some fetching 20x-plus. 

In recent relevant activity, KKR in April agreed to buy Spanish fertility giant Ivirma in a deal valued at €3 billion ($3.2 billion) or more, representing a more than 20x multiple. 

💭 Our thought bubble: It's unclear how hard strategics will run at Inception, but freshly capitalized Ivirma, the largest industry player worldwide, could be a logical suitor if it wants to add to its existing North America footprint in a meaningful way.  

There's also Nordic Capital, which invested in the U.K.'s CARE Fertility in January and hinted at plans to support management with its "international growth ambitions."

Catch up quick: Lee Equity invested in what was then known as Prelude Fertility in 2017, merging it in 2019 with Inception Fertility.

Waypoint Capital joined as an investor in 2018. 

State of play: The process comes as broader macro issues and the financing markets deter many scaled assets from going to market, with few billion-dollar-plus health care services processes still alive. 

That said, direct lenders have continued to step up for high-quality assets as the syndicated market sits on the sidelines. 

Yes, and: The Roe v. Wade reversal and potential ramifications continue to dominate headlines in women's health.

On June 24, Inception said, "Today’s ruling does not limit or prohibit Inception’s ability to provide high-quality IVF as we always have, and none of the 'trigger' laws taking effect in the states where we operate will do so either." 

While questions remain unanswered as to the impact of egg storage in certain states, sponsors so far believe the ruling won't impede industry demand.  And, one source adds, "women's health is high on [investors'] lists."

Still,  depending on what regulators in purple states decide, it may require IVF clinics in certain geographies to make operational or logistical changes, sources note.

Between the lines: All of this noise could be offset by fertility care's strong supply-demand dynamics and scarcity value. 

The market is also witnessing growth in employer coverage, while technology advancements that support higher success rates could yield cost savings.

The list of PE-backed fertility platforms is fairly short, but there's a long runway to consolidate solo practitioners.

Other sponsor-backed players include Amulet Capital's US Fertility, Webster Equity Partners' Santa Monica Fertility, Morgan Stanley Capital Partners' Ovation Fertility and InTandem Capital's Ivy Fertility. 

Yes, and: Despite how timely and costly IVF treatment remains, volume for services is often characterized as growing at a more than 10% CAGR — outpacing the growth of other specialties in provider-land, sources note. 

That dynamic could insulate the industry from pressures of labor shortages and wage inflation — perhaps making it more investable.

The bottom line: Inception's outcome and price are still TBD, but a successful trade could represent a bellwether for fertility, particularly against today's political and regulatory backdrop.

Inception and Moelis declined to comment, while Lee did not return requests for comment. 

Scoop: Lee Equity's Inception Fertility seeks buyer

A successful trade could represent a bellwether for fertility, particularly against today's political and regulatory backdrop.

Illustration of a pregnancy test with a dollar sign appearing on the screen.

Health tech deals

Lee Equity is exploring the sale of Inception Fertility, the largest IVF care provider in the U.S., multiple sources tell Axios.Driving the news: A sale process formally kicked off in June, with first-round bids submitted last week, sources say.

Scoop: Lee Equity's Inception Fertility seeks buyer

What to read next